Fallen blockbusters shake up PBS

Posted 23 February 2026 AM

Topline spending on the PBS grew 10.8 per cent over 2025 to reach $20,836,351,371, despite some big drugs losing exclusivity.

Pharma in Focus analysed data provided by Services Australia on the pre-rebate reimbursements made via the R/PBS to determine the highest-reimbursed innovator brands that are exclusive on the scheme.

To see the whole article, please login

Popular

20+ companies hit PBS bottleneck

Is this pharma's hottest career?

Roche taps Aussie for big HQ job

Obesity battle, now a war of words?

Latest Jobs

Customer Service Representative

Senior Manager, Clinical Operations (Japan)

Senior Clinical Project Manager

Senior Manager, Regulatory Affairs Operations

Associate Director Regulatory Operations (Japan)

See all...

Pharma in Focus Jobs

Marketing & Communications (2)

Sales & Customer Relations (11)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (16)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now